Background Vascular endothelial dysfunction may predict future atherosclerosis. Hence, an
antihypertensive agent that reverses endothelial dysfunction and lowers blood pressure …

Arterial stiffness is a key determinant of cardiovascular risk in hypertensive patients. β-
Blockers appear to be less effective than other drugs in improving outcome in hypertensive …

Although the regulation of arterial blood flow has been a subject of intensive medical
research, the precise circulatory mechanisms involved are still not fully understood. It has …

Nebivolol (Bystolic®) is a cardioselective beta 1 (β1)‐adrenergic receptor blocker with
endothelium‐dependent vasodilating properties. The endothelium‐dependent relaxation …

Background Nebivolol is a new β 1-selective adrenergic receptor antagonist with a direct
vasorelaxant effect that involves activation of the l-arginine–nitric oxide (NO) pathway …

The endothelium is a favourite early target of cardiovascular risk factors and cardiovascular
diseases like hypertension. This key role of the endothelium results from its capacity to …

Essential hypertension is associated with endothelial dysfunction, which is caused mainly by
the production of oxygen-free radicals that can destroy nitric oxide (NO), and impair its …

Essential hypertension is associated with impaired endothelium-dependent vasodilation
and is caused mainly by production of oxygen free radicals that can destroy nitric oxide …

Nebivolol, a racemic mixture of (S, R, R, R) and (R, S, S, S) enantiomers, is the most β 1-
selective adrenoceptor antagonist currently available for clinical use. However, its …

We tested the activity of nebivolol, a β 1-selective blocker with respect to nitric oxide (NO)
and peroxynitrite (ONOO−) generation in the endothelium of normotensive Wistar Kyoto …